此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)

2026年9月28日 更新者:Wills Eye

A Prospective, Randomized Study on the Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)

The purpose of this study is to evaluate whether a preoperative intraocular gas injection improves visual outcomes in patients with a macula-off rhegmatogenous retinal detachment (RRD). While current surgical therapies successfully reattach the retina, visual recovery can vary. This study will investigate if injecting a small amount of gas (0.3 cc of 100% C3F8) into the eye prior to standard surgery can decrease the duration of macular detachment, reduce retinal displacement, and ultimately result in better final visual acuity compared to the standard of care alone.

研究概览

详细说明

Macula-off rhegmatogenous retinal detachment (RRD) is associated with compromised visual outcomes. While current standard-of-care therapies (pars plana vitrectomy and scleral buckle) are highly effective at correcting the anatomy, functional visual recovery remains variable. Time to macular reattachment and the extent of retinal reapposition are critical factors influencing ultimate visual acuity.

Small preliminary studies suggest that an intraocular gas injection performed prior to definitive surgical treatment may decrease the duration of macular detachment and minimize retinal displacement, potentially improving visual outcomes. However, there are currently no randomized controlled trials available to validate this approach.

This randomized study aims to determine if a preoperative injection of 0.3 cc of 100% C3F8 gas prior to standard surgical therapy for macula-off RRD results in superior visual acuity compared to the standard of care alone. By evaluating whether preoperative gas injection effectively shortens the duration of macular separation and reduces retinal displacement, this study seeks to demonstrate a clear visual benefit. Positive findings could change clinical management, establishing a new standard of care and significantly improving the visual prognosis for patients presenting with macula-off RRD.

研究类型

介入性

注册 (估计的)

190

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21287
        • Wilmer Eye Institute, Johns Hopkins Hospital
        • 接触:
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Wills Eye Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • A patient must meet the following criteria to be eligible for inclusion in the study: 1. Diagnosed with macula-involving primary rhegmatogenous retinal detachment 2. Consents to surgical repair with pars plana vitrectomy with or without scleral buckling 3. Willing and able to comply with clinic visits and study-related procedures

Exclusion Criteria:

  • A patient who meets any of the following criteria will be excluded from the study: 1. Age < 18 years old 2. Presence of PVR grade C or worse (as defined by the revised Retina Society PVR classification) at time of surgical repair 3. History of or concurrent ruptured globe, intraocular foreign body, proliferative diabetic retinopathy, retinal vein occlusion, exudative age-related macular degeneration, macular epiretinal membrane, sickle cell disease, uveitis or intraocular infectious diseases 4. Not willing or able to comply with clinic visits and study-related procedures 5. Unable to provide a signed informed consent 6. Unable to maintain positioning to support break 7. Patients that undergo silicone oil placement for primary macula-off RRD 8. For bilateral macula-off RRDs, the better seeing eye will be excluded.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Preoperative Gas

Patients in this group will be injected with 0.3 cc of 100% C3F8 gas prior to surgical repair of the retinal detachment.

Patients with Macula off Rhegmatogenous Retinal Detachment will receive an intravitreal injection of 100% C3F8 prior to undergoing surgical repair for their condition

Patients with RRD will undergo standard of care treatment of RRD with pars plana vitrectomy or pars plana vitrectomy with scleral buckle

有源比较器:Standard of Care

Patients in this arm will receive standard of care treatment with Pars Plana Vitrectomy or Pars Plana vitrectomy with Scleral Buckle.

Patients with RRD will undergo standard of care treatment of RRD with pars plana vitrectomy or pars plana vitrectomy with scleral buckle

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Visual Acuity
大体时间:6 months

Best Corrected Visual Acuity

6 months

次要结果测量

结果测量
措施说明
大体时间
Anatomic Success Rate
大体时间:6 months

Maintenance of retinal attachment and normal retinal structure. Assessed via clinical eye examination, Optical Coherence Tomography Imaging and Fundus autofluorescence.

6 months
Ellipsoid Zone disruption
大体时间:6 months

Examination of presence, and extent of, ellipsoid zone disruption via Optical Coherence Tomography.

6 months
Retinal Displacement
大体时间:6 months

Assessment of presence, and extent, of retinal displacement via clinical eye examination, Optical Coherence Tomography and Fundus autofluorescence

6 months
Metamorphopsia
大体时间:6 months

Assessment of presence, and extent of, metamorphopsia via M-chart examination.

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Ajay Kuriyan, MD、Wills Eye Hospital
  • 首席研究员:Sidra Zafar, MD、The Johns Hopkins Wilmer Eye Institute

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月21日

初级完成 (估计的)

2028年9月1日

研究完成 (估计的)

2029年3月1日

研究注册日期

首次提交

2026年9月28日

首先提交符合 QC 标准的

2026年9月28日

首次发布 (实际的)

2026年10月2日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared to protect patient privacy and confidentiality in accordance with HIPAA regulations and Institutional Review Board (IRB) policies. Only aggregate, de-identified data will be reported in peer-reviewed publications.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅